We conclude that therapies specifically aimed at decreasing plasma ANGPTL3, ANGPTL4, and APOC3 levels are expected to reduce the risk of coronary artery disease without raising safety concerns. The gene discussed is ANGPTL4; the disease is coronary artery disorder.